GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cynata Therapeutics Ltd (ASX:CYP) » Definitions » EV-to-Revenue

Cynata Therapeutics (ASX:CYP) EV-to-Revenue : (As of Jun. 07, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Cynata Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Cynata Therapeutics's enterprise value is A$42.72 Mil. Cynata Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00 Mil. Therefore, Cynata Therapeutics's EV-to-Revenue for today is .

The historical rank and industry rank for Cynata Therapeutics's EV-to-Revenue or its related term are showing as below:

During the past 13 years, the highest EV-to-Revenue of Cynata Therapeutics was 1237.82. The lowest was -15.54. And the median was 327.77.

ASX:CYP's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.94
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-07), Cynata Therapeutics's stock price is A$0.30. Cynata Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00. Therefore, Cynata Therapeutics's PS Ratio for today is .


Cynata Therapeutics EV-to-Revenue Historical Data

The historical data trend for Cynata Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cynata Therapeutics EV-to-Revenue Chart

Cynata Therapeutics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cynata Therapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cynata Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Cynata Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cynata Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cynata Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Cynata Therapeutics's EV-to-Revenue falls into.



Cynata Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Cynata Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=42.722/0
=

Cynata Therapeutics's current Enterprise Value is A$42.72 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cynata Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cynata Therapeutics  (ASX:CYP) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Cynata Therapeutics's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.30/0
=

Cynata Therapeutics's share price for today is A$0.30.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cynata Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cynata Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Cynata Therapeutics (ASX:CYP) Business Description

Traded in Other Exchanges
Address
100 Cubitt Street, Level 3, Cremorne, VIC, AUS, 3121
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinical trials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.

Cynata Therapeutics (ASX:CYP) Headlines

No Headlines